Skip to content
10-Q

Quarterly Report

PharmaCyte Biotech, Inc. PMCB

0001683168-26-001917

← back to feed
Filed
Mar 17, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2026 · Mar 12, 2026 10.74M sh
Shares Diluted Q3 2026 · Jan 31, 2026 9.26M sh
Shares Diluted Q3 2026 · Jan 31, 2026 7.62M sh
Shares Diluted Q3 2026 · Jan 31, 2025 6.96M sh
Shares Diluted Q3 2026 · Jan 31, 2025 7.49M sh
Stock Repurchased Q3 2026 · Jan 31, 2026 $401.63K
Stock Repurchased Q3 2026 · Jan 31, 2025 $2.37M
Operating Cash Flow Q3 2026 · Jan 31, 2026 −$3.76M
Operating Cash Flow Q3 2026 · Jan 31, 2025 −$1.94M
Cash And Equivalents Q3 2026 · Jan 31, 2026 $20.17M
Cash And Equivalents Q3 2026 · Apr 30, 2025 $15.17M
Stockholders Equity Q3 2026 · Jan 31, 2026 $38.11M
Stockholders Equity Q3 2026 · Oct 31, 2025 $35.24M
Stockholders Equity Q3 2026 · Jul 31, 2025 $43.59M
Stockholders Equity Q3 2026 · Apr 30, 2025 $51.89M
Stockholders Equity Q3 2026 · Jan 31, 2025 $40.25M
Stockholders Equity Q3 2026 · Oct 31, 2024 $43.45M
Stockholders Equity Q3 2026 · Jul 31, 2024 $47.71M
Stockholders Equity Q3 2026 · Apr 30, 2024 $27.65M
Current Liabilities Q3 2026 · Jan 31, 2026 $1.68M
Current Liabilities Q3 2026 · Apr 30, 2025 $2.91M
Total Liabilities Q3 2026 · Jan 31, 2026 $16.47M
Total Liabilities Q3 2026 · Apr 30, 2025 $3.28M
Current Assets Q3 2026 · Jan 31, 2026 $20.7M
Current Assets Q3 2026 · Apr 30, 2025 $22.38M
Total Assets Q3 2026 · Jan 31, 2026 $55.87M
Total Assets Q3 2026 · Apr 30, 2025 $55.17M
Eps Diluted Q3 2026 · Jan 31, 2026 −$0.17
Eps Diluted Q3 2026 · Jan 31, 2026 −$2.41
Eps Diluted Q3 2026 · Jan 31, 2025 −$0.44
Eps Diluted Q3 2026 · Jan 31, 2025 $1.67
Eps Basic Q3 2026 · Jan 31, 2026 −$0.17
Eps Basic Q3 2026 · Jan 31, 2026 −$2.41
Eps Basic Q3 2026 · Jan 31, 2025 −$0.44
Eps Basic Q3 2026 · Jan 31, 2025 $1.67
Rd Expense Q3 2026 · Jan 31, 2026 $93.11K
Rd Expense Q3 2026 · Jan 31, 2026 $329.36K
Rd Expense Q3 2026 · Jan 31, 2025 $118.2K
Rd Expense Q3 2026 · Jan 31, 2025 $311.68K
Net Income Q3 2026 · Jan 31, 2026 $746.86K
Net Income Q3 2026 · Jan 31, 2026 −$15.03M
Net Income Q3 2026 · Oct 31, 2025 −$7.42M
Net Income Q3 2026 · Jul 31, 2025 −$8.36M
Net Income Q3 2026 · Jan 31, 2025 −$3.05M
Net Income Q3 2026 · Jan 31, 2025 $18.91M
Net Income Q3 2026 · Oct 31, 2024 −$1.47M
Net Income Q3 2026 · Jul 31, 2024 $23.42M
Operating Income Q3 2026 · Jan 31, 2026 −$2.12M
Operating Income Q3 2026 · Jan 31, 2026 −$4.34M
Operating Income Q3 2026 · Jan 31, 2025 −$960.25K
Operating Income Q3 2026 · Jan 31, 2025 −$3.34M
Revenue Q3 2026 · Jan 31, 2026 $0
Revenue Q3 2026 · Jan 31, 2026 $0
Revenue Q3 2026 · Jan 31, 2025 $0
Revenue Q3 2026 · Jan 31, 2025 $0